TY - JOUR
T1 - High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism
AU - Adorni, Maria Pia
AU - Zimetti, Francesca
AU - Cangiano, Biagio
AU - Vezzoli, Valeria
AU - Bernini, Franco
AU - Caruso, Donatella
AU - Corsini, Alberto
AU - Sirtori, Cesare R.
AU - Cariboni, Anna
AU - Bonomi, Marco
AU - Ruscica, Massimiliano
PY - 2019/6/19
Y1 - 2019/6/19
N2 - Context Low testosterone levels are associated with an increased incidence of cardiovascular (CV) events, but the underlying biochemical mechanisms are not fully understood. The clinical condition of hypogonadism offers a unique model to unravel the possible role of lipoprotein-associated abnormalities in CV risk. In particular, the assessment of the functional capacities of high-density lipoproteins (HDLs) may provide insights besides traditional risk factors. Design To determine whether reduced testosterone levels correlate with lipoprotein function, HDL cholesterol (HDL-C) efflux capacity (CEC) and serum cholesterol loading capacity (CLC). Participants Genetic and idiopathic hypogonadal patients (n = 20) and control subjects (n = 17). Results Primary and secondary hypogonadal patients presented with lower HDL ATP-binding cassette transporter A1 (ABCA1)-, ATP-binding cassette transporter G1 (ABCG1)-, and aqueous diffusion-mediated CEC (-19.6%, -40.9%, and -12.9%, respectively), with a 16.2% decrement of total CEC. In the whole series, positive correlations between testosterone levels and both total HDL CEC (r 2 = 0.359, P = 0.0001) and ABCG1 HDL CEC (r 2 = 0.367, P = 0.0001) were observed. Conversely, serum CLC was markedly raised (+43%) in hypogonadals, increased, to a higher extent, in primary vs secondary hypogonadism (18.45 ± 2.78 vs 15.15 ± 2.10 μg cholesterol/mg protein) and inversely correlated with testosterone levels (r 2 = 0.270, P = 0.001). HDL-C concentrations did not correlate with either testosterone levels, HDL CEC (total, ABCG1, and ABCA1) or serum CLC. Conclusions In hypogonadal patients, proatherogenic lipoprotein-associated changes are associated with lower cholesterol efflux and increased influx, thus offering an explanation for a potentially increased CV risk.
AB - Context Low testosterone levels are associated with an increased incidence of cardiovascular (CV) events, but the underlying biochemical mechanisms are not fully understood. The clinical condition of hypogonadism offers a unique model to unravel the possible role of lipoprotein-associated abnormalities in CV risk. In particular, the assessment of the functional capacities of high-density lipoproteins (HDLs) may provide insights besides traditional risk factors. Design To determine whether reduced testosterone levels correlate with lipoprotein function, HDL cholesterol (HDL-C) efflux capacity (CEC) and serum cholesterol loading capacity (CLC). Participants Genetic and idiopathic hypogonadal patients (n = 20) and control subjects (n = 17). Results Primary and secondary hypogonadal patients presented with lower HDL ATP-binding cassette transporter A1 (ABCA1)-, ATP-binding cassette transporter G1 (ABCG1)-, and aqueous diffusion-mediated CEC (-19.6%, -40.9%, and -12.9%, respectively), with a 16.2% decrement of total CEC. In the whole series, positive correlations between testosterone levels and both total HDL CEC (r 2 = 0.359, P = 0.0001) and ABCG1 HDL CEC (r 2 = 0.367, P = 0.0001) were observed. Conversely, serum CLC was markedly raised (+43%) in hypogonadals, increased, to a higher extent, in primary vs secondary hypogonadism (18.45 ± 2.78 vs 15.15 ± 2.10 μg cholesterol/mg protein) and inversely correlated with testosterone levels (r 2 = 0.270, P = 0.001). HDL-C concentrations did not correlate with either testosterone levels, HDL CEC (total, ABCG1, and ABCA1) or serum CLC. Conclusions In hypogonadal patients, proatherogenic lipoprotein-associated changes are associated with lower cholesterol efflux and increased influx, thus offering an explanation for a potentially increased CV risk.
UR - http://www.scopus.com/inward/record.url?scp=85068117249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068117249&partnerID=8YFLogxK
U2 - 10.1210/jc.2018-02027
DO - 10.1210/jc.2018-02027
M3 - Article
C2 - 30835274
AN - SCOPUS:85068117249
VL - 104
SP - 3097
EP - 3107
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 8
ER -